

# Risk of cancer from reduced expression of PrP<sup>C</sup>-implications for prion disease treatment

Victoria Lawson

Department of Microbiology and Immunology, Peter Doherty Institute  
for Infection and Immunity, The University of Melbourne, Victoria,  
Australia



CREUTZFELDT-JAKOB DISEASE  
FOUNDATION, INC.

*Supporting Families Affected by Prion Disease*



*I acknowledge the Traditional Owners of the land on which this work was performed, the land of the Wurundjeri, and pay respect to their Elders and families.*




Ms Shana Portelli  
Dr Natalia Fortunato  
Dr Marianne Tait  
Ms Portia Swainsbury

Mantamadiotis Group  
Hollande Group

# Summary


- Cancer progression is *driven* (🚗) by the deletion of tumor suppressor genes (*brake off*) and activation of oncogenes (*accelerator on*).




- We have investigated the effect of PrP<sup>C</sup> expression in two models of brain cancer to determine whether treatment of prion disease with ASO to decrease expression of PrP<sup>C</sup> could affect cancer risk.

- In a low-grade brain cancer model (brake off) the absence of PrP<sup>C</sup> expression was associated with larger more invasive tumor cells.
- In a high-grade brain cancer model (brake off/accelerator on) the absence of PrP<sup>C</sup> expression was associated with reduced tumor cell proliferation.
- These observations suggest that PrP<sup>C</sup> has a complex role in cancer progression and that prolonged changes in PrP<sup>C</sup> expression through therapeutic intervention could inadvertently increase the risk of cancer in some individuals.
- We are using spatial gene expression to better understand how PrP<sup>C</sup> contributes to brain cancer.

# PrP<sup>C</sup> : cell death or proliferation



# PrP<sup>C</sup> : cell death or proliferation




# The role of PrP<sup>C</sup> in cancer




Increased PrP<sup>C</sup> expression in cancer:

- Brain (Luo et al., 2020)
- Breast (Dèry et al., 2013)
- Colorectal (Le Corre et al., 2019)
- Gastric (Liang et al., 2006)
- Pancreatic (Bianchini et al., 2021)
- Melanoma (Li et al., 2010)

Control brain



Grade 4 Glioblastoma



**PrP<sup>C</sup> labelling by immunohistochemistry.**  
(Luo et al., 2020)

Increased PrP<sup>C</sup> expression shown to correlate with:

1. Increased tumour grade

(Luo et al., 2020)



2. Tumour recurrence

(Du et al., 2013)



3. Reduced patient survival

(Zhou et al., 2014)


4. Increased therapy resistance

(Zhuang et al., 2012)



# The role of PrP<sup>C</sup> in cancer




## The Hallmarks of Cancer




- Altered PrP<sup>C</sup> expression may perturb or exacerbate physiological functions, which have been linked to cancer hallmarks
- Interaction between PrP<sup>C</sup> and signaling networks may facilitate these roles e.g., [Notch1](#), [ERK1/2](#), [PI3K/Akt](#)<sup>1</sup>

<sup>1</sup>Wang et al., 2016; Provenzano et al., 2017; Liang et al., 2009


# Cancer progression




On      Off



Off      Off



Off      On






NORMAL



BENIGN

MALIGNANT




# Cancer progression



Tumor suppressor gene



Oncogene






NORMAL




BENIGN

MALIGNANT




# Cancer progression






Cancer genes






# Cancer progression



Cancer genes



# Cancer progression



Cancer genes





On Off




Off Off



Off On



# PrP<sup>C</sup> and cancer progression




# Brain cancer model

Low-grade (*Pten*)

*Prnp*<sup>-/-</sup>




*Prnp*<sup>+/+</sup>



High-grade (*Pik3ca-Pten*)


*Prnp*<sup>-/-</sup>



*Prnp*<sup>+/+</sup>







# Low- and high-grade cell models of glioma with PrP<sup>C</sup> knockout and wild-type expression






NSPC = neural stem progenitor cell  
 SVZ = sub-ventricular zone

# PrP<sup>C</sup> and brain cancer progression






# Absence of PrP<sup>C</sup> increases proliferation in a low-grade brake off/accelerator off (*Pten*) mutant cell model



Cell counts performed in duplicate from separate wells  
 Two-way ANOVA, followed by Tukey's multiple comparisons test; \*\*\*\**P* < 0.0001  
 Scale bar = 500μm


# Absence of PrP<sup>C</sup> reduces proliferation in a high-grade brake off/accelerator on (*Pik3ca/Pten*) mutant cell model



Cell counts performed in duplicate from separate wells  
Two-way ANOVA, followed by Tukey's multiple comparisons test; \*\*\*\**P* < 0.0001

Scale bar = 500μm


# Absence of PrP<sup>C</sup> has differing effects on low- and high-grade cell models of glioma



Malignancy

In the absence of PrP <sup>C</sup>		<i>Pten</i>	<i>Pik3ca/Pten</i>
	<b>Proliferation</b>	Increased	Reduced
	<b>Viability</b>	No effect	Trend to reduced
	<b>Sphere forming efficiency</b>	Increased	No effect
	<b>Neurosphere size</b>	Increased	Reduced
	<b>Neurosphere number</b>	Increased	No effect
	<b>Invasion</b>	Increased	Trend to reduced

# The role of PrP<sup>C</sup> in glioma tumour initiation and progression



# The role of PrP<sup>C</sup> in glioma tumour initiation and progression

PrP<sup>C</sup> KO


PrP<sup>C</sup> HET

PrP<sup>C</sup> WT


*Pten*




Off Off



200 μm



200 μm






200 μm





*Pik3ca-  
Pten*



Off On




# Absence of PrP<sup>C</sup> promotes tumour size in low-grade brake off/accelerator off (*Pten*) mutant mouse model 6-weeks post induction




N = 5 each *Prnp* genotype  
 One-way ANOVA, followed by Tukey's multiple comparisons test; ns = not significant, \*P < 0.05  
 Scale bar = 200µm

# Increased cell density at leading edge of PrP<sup>C</sup> knockout low-grade brake off/accelerator off (*Pten*) mutant tumours (6-week t.p.)



*Prnp*<sup>-/-</sup>



*Prnp*<sup>+/-</sup>





*Prnp*<sup>+/+</sup>



*N* = 5 each *Prnp* genotype. Scale bar = 50µm

# Visium Spatial Gene Expression

6 weeks post induction



## Progress update:

1. Visium sample preparation
2. Visium workflow
3. Generation of Visium libraries
4. Sequencing
5. Analysis



# Acknowledgements



CREUTZFELDT-JAKOB DISEASE  
FOUNDATION, INC.

*Supporting Families Affected by Prion Disease*

We are grateful for the support of:

- The Strides for CJD Research Grant
- The CJD Foundation Research Grant